MOG (35-55): Gold Standard Peptide for Experimental Autoimmune Encephalomyelitis Research

Executive Summary: MOG (35-55) is a 21-amino-acid peptide derived from human myelin oligodendrocyte glycoprotein (MOG), extensively validated for inducing experimental autoimmune encephalomyelitis (EAE) in mouse models of multiple sclerosis (MS) (APExBIO). Its administration triggers strong, reproducible T and B cell-mediated autoimmunity, leading to MS-like demyelination and neuroinflammation (Xu et al., 2025). MOG (35-55) enables mechanistic dissection of neuroimmune pathways, such as the STAT1/STAT2 interferon axis, and provides a benchmark for testing immunomodulatory therapies. The peptide demonstrates precise solubility and stability parameters critical for consistent experimental outcomes. APExBIO's MOG (35-55) (SKU: A8306) is recognized for purity, reproducibility, and robust translational value in MS research (MHC-Class-II-Antigen.com).

Biological Rationale

MOG (35-55) is a truncated peptide corresponding to amino acids 35–55 of the human myelin oligodendrocyte glycoprotein. MOG is a member of the immunoglobulin superfamily and is located on the outermost surface of central nervous system myelin. The peptide is highly immunogenic and contains the dominant epitope recognized by autoreactive T cells in both rodent and human multiple sclerosis models (Xu et al., 2025). Immunization with MOG (35-55) induces robust EAE, which recapitulates critical pathological features of MS, including demyelination, neuroinflammation, and relapsing-remitting neurological impairment (see also).

In contrast to full-length MOG or other CNS antigens, the MOG (35-55) peptide enables reproducible disease onset and severity across susceptible mouse strains, especially when administered with complete Freund's adjuvant (CFA). This property makes it the gold standard for preclinical studies of autoimmune encephalomyelitis (MOG35-55.com provides additional protocol details, whereas this article emphasizes mechanistic and translational updates).

Mechanism of Action of MOG (35-55)

MOG (35-55) acts as a potent immunogen. Upon subcutaneous or intradermal injection with CFA, it is taken up by antigen-presenting cells (APCs) such as dendritic cells. The peptide is processed and presented on MHC class II molecules, activating naïve CD4⁺ T cells. This leads to the clonal expansion of autoreactive Th1 and Th17 cells, which migrate to the central nervous system (Xu et al., 2025).

Activated T cells secrete pro-inflammatory cytokines (e.g., IFN-γ, IL-17), disrupt the blood-brain barrier, and promote infiltration of B cells and macrophages. B cells recognize the MOG (35-55) epitope, producing autoantibodies that mediate complement activation and demyelination. In vitro, MOG (35-55) stimulates NADPH oxidase and matrix metalloproteinase-9 (MMP-9) activity in immune cells, contributing to oxidative stress and extracellular matrix remodeling—key features of MS pathology (3-Deazaneplanocin.com explores these mechanisms in depth, while this article integrates recent advances in interferon signaling).

Recent work highlights the intersection of MOG (35-55)-induced EAE and type I interferon pathways. PARP7, a mono-ADP-ribosyltransferase, suppresses type I interferon signaling by promoting autophagic degradation of STAT1/STAT2. Inhibition of PARP7 stabilizes STAT1/STAT2, restoring interferon activity and ameliorating EAE symptoms induced by MOG (35-55) (Xu et al., 2025, Cell Reports).

Evidence & Benchmarks

• MOG (35-55) at doses of 50–150 μg induces severe, rapid-onset EAE in C57BL/6J and HLA-DR2 transgenic mice, with reproducible clinical scores and demyelination (Xu et al., 2025).
• The peptide is soluble at ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO at room temperature; it is insoluble in ethanol (see APExBIO product page).
• Stock solutions (0.50 mg/mL in sterile water, with warming and ultrasonic bath) retain activity for at least 24 hours at 4°C but should be stored desiccated at -20°C for long-term stability (see Immuneland.com for detailed protocols).
• MOG (35-55) increases NADPH oxidase and MMP-9 activities in immune cell assays, supporting its use in oxidative stress and neuroinflammation studies (3-Deazaneplanocin.com).
• PARP7 inhibition in MOG (35-55)-EAE models results in stabilization of STAT1/STAT2 and significant reduction in clinical severity, linking EAE pathogenesis to interferon signaling modulation (Xu et al., 2025).

Applications, Limits & Misconceptions

MOG (35-55) is the preferred experimental autoimmune encephalomyelitis inducer for modeling relapsing-remitting and chronic-progressive MS in rodents. It is widely used in neuroinflammation assays, T and B cell immune response induction, and in vivo pharmacological screening of immunotherapies. The peptide is also applicable in studies of oxidative stress, blood-brain barrier disruption, and matrix remodeling.

However, its use is restricted to species and strains with compatible MHC class II molecules (e.g., H-2^b in C57BL/6 mice). MOG (35-55) does not recapitulate all facets of MS—particularly the full spectrum of human lesion heterogeneity. Disease induction requires precise dosing and adjuvant protocols; variations can result in inconsistent disease onset or severity.

Common Pitfalls or Misconceptions

• MOG (35-55) is not universally effective: It fails to induce EAE in mouse strains lacking the appropriate MHC class II alleles (e.g., H-2^d or H-2^k). Disease susceptibility is genetically determined (Xu et al., 2025).
• Adjuvant selection is critical: Omission or improper preparation of complete Freund's adjuvant leads to poor or absent EAE induction.
• Peptide solubility and storage: Ethanol should not be used as a solvent; incorrect storage (e.g., repeated freeze-thaw cycles, non-desiccated conditions) decreases activity.
• Not a direct therapy: MOG (35-55) is a research reagent for modeling, not a treatment for MS or other autoimmune diseases.
• Model limitations: MOG (35-55)-induced EAE primarily models inflammatory demyelination but does not fully capture chronic neurodegeneration or remyelination seen in late-stage MS.

Workflow Integration & Parameters

For effective induction of EAE, MOG (35-55) should be prepared in sterile water at 0.50 mg/mL, with warming and ultrasonic bath to enhance dissolution. Use ≥32.25 mg/mL in water or ≥86 mg/mL in DMSO for concentrated stock. The working solution must be freshly prepared and used within 24 hours or stored at -20°C (desiccated) for extended periods. Avoid repeated freeze-thaw cycles to prevent peptide degradation (APExBIO).

In vivo, administer 50–150 μg per mouse subcutaneously, typically emulsified in an equal volume of CFA. Monitor clinical symptoms and body weight daily. For in vitro assays, titrate peptide concentrations (e.g., 1–100 μg/mL) to assess immune cell responses, including cytokine production, NADPH oxidase, and MMP-9 activities.

For advanced protocol guidance, this article extends previous work by mapping the regulatory role of PARP7 and STAT1/STAT2 in MOG (35-55)-EAE models, offering translational insights for future neuroimmunology research.

Conclusion & Outlook

MOG (35-55) (APExBIO, A8306) remains the reference peptide for reliable induction of EAE and translational multiple sclerosis research. Its well-characterized immunodominant epitope enables reproducible modeling of neuroinflammation, demyelination, and adaptive immune responses. Emerging evidence links EAE severity to the regulation of interferon signaling via PARP7 and STAT1/STAT2, broadening the mechanistic utility of MOG (35-55) for preclinical therapeutic screening (Xu et al., 2025). Proper handling, dosing, and strain selection are essential for experimental success. As research advances, MOG (35-55)-based models will continue to provide critical insights into autoimmune pathogenesis and the development of next-generation therapies for MS.